A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients

Completed · Phase 3

Conditions studied: Hypertension

In brief

The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the mechanism of action of nebivolol on forearm blood flow, nitric oxide availability and other biomarkers.

Key facts

Study ID

NCT00648895

Run by

Forest Laboratories

People needed

12

Starts

2007-11-01

Last updated by the study team

2010-09-20

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, ambulatory outpatients 18-79 years old at screening
• Minimum 2-year history of Stage I/II hypertension
• Qualifying blood pressure criteria for study entry and for randomization
• Willing to adhere to the dietary compliance and undergo protocol procedures
• Have a lifestyle that will permit him/her to attend all evaluations, including those conducted on consecutive days

You may not qualify if…

• Have any form of secondary hypertension
• Have clinically significant respiratory or cardiovascular disease
• Presence/history of coronary artery disease or peripheral vascular disease
• Have diabetes mellitus, Type I or II
• Have a history of hypersensitivity to nebivolol, metoprolol, or any beta-blocker

Where it is running

• Forest Investigative Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.